Management of Common Symptoms in Terminally Ill Patients: Part II. Constipation, Delirium and Dyspnea



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

In addition to pain, patients who are approaching the end of life commonly have other symptoms. Unless contraindicated, prophylaxis with a gastrointestinal motility stimulant laxative and a stool softener is appropriate in terminally ill patients who are being given opioids. Patients with low performance status are not candidates for surgical treatment of bowel obstruction. Cramping abdominal pain associated with mechanical bowel obstruction often can be managed with morphine (titrating the dosage for pain) and octreotide. Delirium is common at the end of life and is frequently caused by a combination of medications, dehydration, infections or hypoxia. Haloperidol is the pharmaceutical agent of choice for the management of delirium. Dyspnea, the subjective sensation of uncomfortable breathing, is often treated by titration of an opioid to relieve the symptom; a benzodiazepine is used when anxiety is a component of the breathlessness.

Physical symptoms other than pain often contribute to suffering at the end of life. Part I of this two-part article reviewed the management of fatigue, anorexia, cachexia, nausea and vomiting in patients with cancer, acquired immunodeficiency syndrome (AIDS) and other terminal illnesses. Part II discusses measures to alleviate constipation, delirium and dyspnea. With appropriate diagnosis and management, many of these symptoms can be alleviated in patents who are approaching the end of life.

Constipation

Constipation is a frequent cause of nausea and vomiting in terminally ill patients. Management depends on assessment and manipulation of the four major components required for normal bowel movements: intestinal solids, water, motility and lubrication (Table 1).1

Constipation resulting from opioids is dose-related, and patients do not develop tolerance to this side effect. Prophylaxis is crucial because opioid-induced constipation is much easier to prevent than to treat. All patients for whom opioids are prescribed should be given a prophylactic gastrointestinal motility stimulant laxative and a stool softener, unless use of these agents is contraindicated. A stool softener alone is usually not sufficient to alleviate opioid-induced constipation.

BOWEL OBSTRUCTION

Mechanical bowel obstruction occurs in approximately 3 percent of patients with cancer who are receiving hospice care.2 It is most frequently associated with ovarian and colon cancers. In terminally ill patients with low performance status, surgical treatment of bowel obstruction is not appropriate because of high mortality and recurrence rates.2

Cramping abdominal pain associated with mechanical bowel obstruction primarily results from the accumulation of secreted bowel fluid. This problem can often be managed with titration of the morphine dosage to manage pain, along with the administration of octreotide (Sandostatin), a synthetic somatostatin that inhibits the intraluminal secretion of intestinal fluid.

Treatment with medications commonly used to manage nausea and vomiting (e.g., haloperidol [Haldol], diphenhydramine [Benadryl], octreotide) should also be considered. (Use of these drugs is discussed in part I of this two-part article.) The exception is the prokinetic agent metoclopramide (Reglan), which may worsen symptoms of mechanical obstruction. Stool softeners and osmotic agents may be useful in patients with partial mechanical obstruction.

Delirium

Delirium is a disturbance of consciousness and cognition with a sudden onset that may be accompanied by increased psychomotor activity.3 This symptom occurs in 25 to 85 percent of terminally ill patients.4,5 Mental status changes can be very distressing to the family, who observe agitation, apparent fear or what they believe to be uncontrolled pain in the patient. Delirium often heralds the end of life and may require active sedation in up to 25 percent of patients.4

TABLE 1

End-of-Life Care: Treatment of Constipation by Manipulation of Factors Affecting Bowel Movements

Factor Etiologic event Correction or treatment Comments

Low intestinal solids

Low-fiber diet

Psyllium

Caution is advised in patients with low fluid intake, as psyllium may cause impaction

Low stool water content

Dehydration, reduced intestinal secretion, slow transit time of stool

Hyperosmolar nonabsorbable agents

Magnesium salts

Contraindicated in patients with renal failure

Phosphorous salts

Contraindicated in patients with renal failure

Glycerin suppositories

Sorbitol (30 mL every 2 to 4 hours until stool)

Sickly sweet taste; may cause cramps

Lactulose (30 mL orally every 4 to 6 hours)

Low gastrointestinal motility

Bed-ridden patients; neurodegenerative disorders; drugs, including morphine, tricyclic antidepressants, scopolamine (Transderm Scop), diphenhydramine (Benadryl), vincristine (Oncovin), verapamil (Calan) and other calcium channel blockers, iron, aluminum and calcium salts

Senna

Stimulates myenteric plexus

Bisacodyl

Prune juice

Inexpensive, effective

Casanthranol

Poor gastrointestinal lubrication

Dehydration

Dioctyl sodium sulfosuccinate

Inadequate alone to counteract opioid-induced constipation

Mineral oil enemas

Do not give mineral oil by mouth, as aspiration may cause pneumonitis.

Glycerin suppositories


Adapted with permission from Hallenbeck J, Weissman D. Fast fact and concepts #15: Constipation—what makes us go. June, 2000. End-of-Life Physician Education Resource Center. Retrieved April 23, 2001, from: http://www.eperc.mcw.edu.

TABLE 1   End-of-Life Care: Treatment of Constipation by Manipulation of Factors Affecting Bowel Movements

View Table

TABLE 1

End-of-Life Care: Treatment of Constipation by Manipulation of Factors Affecting Bowel Movements

Factor Etiologic event Correction or treatment Comments

Low intestinal solids

Low-fiber diet

Psyllium

Caution is advised in patients with low fluid intake, as psyllium may cause impaction

Low stool water content

Dehydration, reduced intestinal secretion, slow transit time of stool

Hyperosmolar nonabsorbable agents

Magnesium salts

Contraindicated in patients with renal failure

Phosphorous salts

Contraindicated in patients with renal failure

Glycerin suppositories

Sorbitol (30 mL every 2 to 4 hours until stool)

Sickly sweet taste; may cause cramps

Lactulose (30 mL orally every 4 to 6 hours)

Low gastrointestinal motility

Bed-ridden patients; neurodegenerative disorders; drugs, including morphine, tricyclic antidepressants, scopolamine (Transderm Scop), diphenhydramine (Benadryl), vincristine (Oncovin), verapamil (Calan) and other calcium channel blockers, iron, aluminum and calcium salts

Senna

Stimulates myenteric plexus

Bisacodyl

Prune juice

Inexpensive, effective

Casanthranol

Poor gastrointestinal lubrication

Dehydration

Dioctyl sodium sulfosuccinate

Inadequate alone to counteract opioid-induced constipation

Mineral oil enemas

Do not give mineral oil by mouth, as aspiration may cause pneumonitis.

Glycerin suppositories


Adapted with permission from Hallenbeck J, Weissman D. Fast fact and concepts #15: Constipation—what makes us go. June, 2000. End-of-Life Physician Education Resource Center. Retrieved April 23, 2001, from: http://www.eperc.mcw.edu.

As one investigator noted, “All episodes of delirium . . . interfere with meaningful interpersonal contact with loved ones due to clouding of consciousness.”4 Because the period before death can be a last chance for the patient and family members to mend relationships, share dreams and say good-bye, it is imperative that measures be instituted to control delirium.

Common causes of delirium near death include hypoxia, infections (e.g., simple urinary tract infection), fever, dehydration and opioid or benzodiazepine withdrawal. As the time of death approaches, hepatic and renal function deteriorates, and patients become more vulnerable to delirium, particularly delirium caused by medications. Discontinuing unnecessary drugs or prolonging the dosing interval for necessary drugs may help to clear the sensorium.

A recent study5 found that despite a high incidence (88 percent), delirium was reversible in approximately 50 percent of dying patients. In this study, opioids, other psychoactive medications and dehydration were the most frequent causes of reversible delirium. Dehydration is usually asymptomatic in terminally ill patients; however, when dehydration results in delirium, gentle rehydration may be beneficial if there is a need for the patient to be more alert.

Another study6 identified factors associated with an increased risk of delirium in patients older than 80 years. These risk factors included impaired vision (Snellen test score worse than 20/70), severe illness (Acute Physiology and Chronic Health Evaluation II score higher than 16), cognitive impairment (Mini-Mental State Examination score lower than 24) and dehydration (blood urea nitrogen level higher than 18 mg per dL [6.5 mmol per L]).

In addition to reducing risk factors for delirium, the physician may be able to prevent its onset in an elderly patient by avoiding five precipitating conditions: the use of physical restraints, malnutrition, the addition of more than three new medications in one day, the use of bladder catheterization, and iatrogenic events such as frequent room or staff changes or a disruptive environment with excess noise that may disrupt sleep.6,7

Altered mental status may be precipitated by a combination of therapies. Anesthetics, analgesics, antibiotics, anticholinergics, antihypertensives, antiarrhythmics, anticonvulsants, histamine H1 and H2 antagonists, and other drugs have been associated with the onset of delirium in patients treated in intensive care units (ICUs).7 According to one group of investigators,7 what has been called “ICU psychosis (or syndrome)” is actually a true delirium caused by organic stressors; as such, it should be promptly noted and aggressively managed, rather than tolerated or ignored.

The two goals of symptomatic care in the dying patient are to determine the cause of the mental status symptoms and to institute measures to control these symptoms as they affect the quality of life for the patient and family. Hospice workers often observe “terminal restlessness” as a sign that death is approaching.8 If delirium occurs close to the time of death, the patient's agitation may simply be observed, with attention given to preventing physical harm. Alternatively, the patient may require sedation for the comfort of all involved in care. Terminal sedation is a treatment of last resort and is beyond the scope of this article. Full discussions of this subject are available in the literature.911

Hospice workers have noted that a changed mental status is more pronounced in patients who have been undergoing a significant psychosocial or spiritual struggle. They would argue that sedation is not appropriate in this setting. For families, however, the open, staring eyes and agitated movement of a patient may not be emotionally tolerable, resulting in a request for something to “quiet” the patient.

TABLE 2
Medications Commonly Used to Manage Delirium in End-of-Life Care

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

Haloperidol is the agent of choice for the management of delirium associated with hyperactivity at the end of life. A well-designed, double-blind study8 comparing haloperidol (a high-potency neuroleptic), chlorpromazine (a low-potency neuroleptic) and lorazepam (a benzodiazepine) in the treatment of delirium in hospitalized patients with AIDS found haloperidol to be the preferred drug. Greater improvement of mental status symptoms occurred within 24 hours after the initiation of haloperidol in a low dosage (2.8 mg per day)8,12 than with neuroleptics given in previous trials.13 No extra-pyramidal side effects were noted. The benzodiazepine arm was terminated before the end of the trial8  because of paradoxic agitation or oversedation. Studies have not been completed in other patient populations; thus, it is not clear whether these findings are true for all terminally ill patients. Medications commonly used to manage delirium are listed in Table 2.14

Nonpharmacologic interventions for delirium can also be of benefit. For example, a family member or other person (e.g., a sitter) might remain with the patient to keep the patient calm and prevent physical harm. Use of physical restraints should be avoided unless absolutely necessary; if required, restraints should be used in conjunction with sedation.

Patients' descriptions of “visits” by loved ones who have died before them should not be mistaken for delirium or confusion. Although labeled by some as hallucinations, these encounters usually appear to be comforting to dying patients and consequently may not require medical treatment.

Dyspnea

Dyspnea, which is a subjective experience of difficult or distressed breathing, has been described in patients with cancer (70 percent), AIDS (11 to 62 percent) and other terminal illnesses.15(pp 295–308)–20 One study21 noted that family physicians find dyspnea to be the most distressing symptom in dying patients.

Objective findings may not adequately reflect the distress experienced by patients with dyspnea. The original hospice studies20 conducted during the late 1980s found that 75 percent of patients with cancer and lung involvement had dyspnea; however, of those with dyspnea who were entered in hospice programs, only 39 percent had primary lung problems. In the same studies, fully 24 percent of patients with dyspnea had no obvious etiology for the symptom. Hence, not all patients with dyspnea have severe pulmonary pathology or tachypnea, and vice versa. This distinction is important because symptomatic treatments are directed toward the end point of relieving the symptom (dyspnea), not the sign (tachypnea).

The pathophysiology of dyspnea can reflect the regulation of breathing (central, psychiatric), the act of breathing (weakened intercostal muscles) or the need to alter breathing patterns because of increased activity or hypoxia.22,23 Tools for measuring dyspnea include the Medical Research Council method,24 the Support Team Assessment Schedule25 and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30; used in many cancer studies).26 In addition, a visual analog or numeric scale can be employed at the bedside to record the degree of dyspnea experienced by the patient.

The treatment of dyspnea is best directed at the underlying cause (if known). Some causes and appropriate interventions are listed in Table 3.15(pp 295–308) The most common reversible causes of dyspnea are bronchospasm (52 percent), hypoxia (40 percent) and anemia (20 percent).27

When dyspnea is not reversible by specific cause-directed treatment, symptomatic treatment is given (Table 4). Opiates, titrated to achieve the desired effect with acceptable toxicity, are considered the mainstay of the symptomatic treatment of dyspnea. In some studies,28,29 opiates have been reported to increase exercise tolerance and reduce the perception of breathlessness in patients with chronic obstructive pulmonary disease. Other studies3032 have not been able to substantiate this benefit. More clinical trials are needed.

A recent study33 at St. Christopher's Hospice in London found that titrated oral morphine improved dyspnea in 60 percent of patients with terminal cancer. However, significant short-term adverse effects (particularly sedation) occurred, causing some patients to drop out of the trial. The authors of the study advised physicians to inform patients with dyspnea about the side effects of opioids and to monitor carefully for such effects.

TABLE 3

Recommended Treatments for Dyspnea in End-of-Life Care Based on Etiology*

Etiology Treatment

Anemia

Transfusion, erythropoietin†

Hypoxia

Increase fraction of inspired oxygen.

Superior vena cava compression

Radiation; corticosteroids in high dosage

Lymphangitic tumor spread

Corticosteroids in high dosage (short term only)

Pleural effusion

Thoracentesis, chest tube, pleurodesis

Pericardial effusion

Aspiration, pericardial window

Cardiovascular disease

Diuretic, possible irradiation

Pulmonary embolus

Anticoagulation, possible filter (antibiotics)

Chronic obstructive pulmonary disease

Bronchodilators (aerosolized), corticosteroids, antibiotics

Infections

Antibiotics, antifungals or antivirals; corticosteroids

Anxiety

Benzodiazepines, environmental interventions


*—See also Table 4.

†—The physician can decide if it is reasonable to use erythropoietin in a terminally ill patient. Although treatment can be beneficial in relieving fatigue and improving quality of life, it is expensive and must be given for 4 to 6 weeks before benefits become apparent. Giving a dosage of 10,000 units daily for two weeks may reduce this time.

Adapted with permission from Berger A, Portenoy RK, Weissman DE, eds. Principles and practice of supportive oncology. Philadelphia: Lippincott-Raven, 1998: 295–308.

TABLE 3   Recommended Treatments for Dyspnea in End-of-Life Care Based on Etiology*

View Table

TABLE 3

Recommended Treatments for Dyspnea in End-of-Life Care Based on Etiology*

Etiology Treatment

Anemia

Transfusion, erythropoietin†

Hypoxia

Increase fraction of inspired oxygen.

Superior vena cava compression

Radiation; corticosteroids in high dosage

Lymphangitic tumor spread

Corticosteroids in high dosage (short term only)

Pleural effusion

Thoracentesis, chest tube, pleurodesis

Pericardial effusion

Aspiration, pericardial window

Cardiovascular disease

Diuretic, possible irradiation

Pulmonary embolus

Anticoagulation, possible filter (antibiotics)

Chronic obstructive pulmonary disease

Bronchodilators (aerosolized), corticosteroids, antibiotics

Infections

Antibiotics, antifungals or antivirals; corticosteroids

Anxiety

Benzodiazepines, environmental interventions


*—See also Table 4.

†—The physician can decide if it is reasonable to use erythropoietin in a terminally ill patient. Although treatment can be beneficial in relieving fatigue and improving quality of life, it is expensive and must be given for 4 to 6 weeks before benefits become apparent. Giving a dosage of 10,000 units daily for two weeks may reduce this time.

Adapted with permission from Berger A, Portenoy RK, Weissman DE, eds. Principles and practice of supportive oncology. Philadelphia: Lippincott-Raven, 1998: 295–308.

Given these caveats, many physicians who provide palliative care manage dyspnea with opioids administered by oral, subcutaneous and inhaled (nebulizer) routes, with the dosage titrated to a level at which the symptom is relieved. Benzodiazepines, titrated until dyspnea is relieved, are commonly added to the opioid regimen to alleviate the anxiety associated with breathlessness.

TABLE 4

Symptomatic Management of Dyspnea in End-of-Life Care

Nonpharmacologic therapy

Promote good air movement around the patient.

Provide cool room temperature, as tolerated by the patient.

Explain to the family that external signs (e.g., tachypnea) may not indicate patient discomfort.

Humidify the air that the patient breathes.

Maintain the patient in a sitting position.

Minimize the patient's distress by encouraging the family to avoid having disagreements in front of the patient.

Minimize the patient's exertion by providing a bedside commode and transporting the patient by wheelchair; avoid exposure to hot, humid weather and extreme temperatures.

Provide postural drainage.

Have the nursing staff or family give the patient massages and provide distraction with music or by reading aloud to the patient.

Provide oxygen, or a fan in the patient's room.

Visit the patient.

Consult the hospice team.

Pharmacologic therapy

Opioids*

Mild dyspnea

Hydrocodone, 5 mg orally every 4 hours

Acetaminophen-codeine (Phenaphen; 325 mg/30 mg), one capsule orally every 4 hours

Severe dyspnea

Morphine, 5 mg orally; titrate dose every 4 hours.

Oxycodone (Roxicodone), 5 mg orally; titrate dose every 4 hours.

Hydromorphone (Dilaudid), 0.5 to 2 mg orally; titrate dose every 4 hours.

Benzodiazepines: titrate dosage to reduce anxiety component.

Bronchodilators

Corticosteroids


*—In opiate-naïve patients, use the listed starting dosage and titrate until symptoms are relieved.

TABLE 4   Symptomatic Management of Dyspnea in End-of-Life Care

View Table

TABLE 4

Symptomatic Management of Dyspnea in End-of-Life Care

Nonpharmacologic therapy

Promote good air movement around the patient.

Provide cool room temperature, as tolerated by the patient.

Explain to the family that external signs (e.g., tachypnea) may not indicate patient discomfort.

Humidify the air that the patient breathes.

Maintain the patient in a sitting position.

Minimize the patient's distress by encouraging the family to avoid having disagreements in front of the patient.

Minimize the patient's exertion by providing a bedside commode and transporting the patient by wheelchair; avoid exposure to hot, humid weather and extreme temperatures.

Provide postural drainage.

Have the nursing staff or family give the patient massages and provide distraction with music or by reading aloud to the patient.

Provide oxygen, or a fan in the patient's room.

Visit the patient.

Consult the hospice team.

Pharmacologic therapy

Opioids*

Mild dyspnea

Hydrocodone, 5 mg orally every 4 hours

Acetaminophen-codeine (Phenaphen; 325 mg/30 mg), one capsule orally every 4 hours

Severe dyspnea

Morphine, 5 mg orally; titrate dose every 4 hours.

Oxycodone (Roxicodone), 5 mg orally; titrate dose every 4 hours.

Hydromorphone (Dilaudid), 0.5 to 2 mg orally; titrate dose every 4 hours.

Benzodiazepines: titrate dosage to reduce anxiety component.

Bronchodilators

Corticosteroids


*—In opiate-naïve patients, use the listed starting dosage and titrate until symptoms are relieved.

Nonpharmacologic measures can also be of great value. Interventions include providing good air movement near the patient, keeping cool room temperatures, and proposing and instituting measures to minimize the patient's exertion or anxiety. Movement of air by a fan may calm the patient. The administration of oxygen or air can significantly reduce dyspnea in patients with advanced cancer.34

Measures designed to minimize stress can be useful in treating dyspnea. Exertion on the part of the patient can be limited by providing a bedside commode, using a wheelchair for transport and avoiding exposure to hot, humid weather or extreme temperatures. Postural drainage techniques may be helpful. Family members should be taught to inquire specifically about the patient's comfort, in that external signs may appear quite distressing to the family but may not seem unusual to the patient. Family members and friends can lessen the patient's distress by avoiding disagreements in front of the patient.

Patients with dyspnea often prefer sitting with their body leaning forward and their arms resting on a table. Prolonged use of this position may result in muscle aches and soreness, which can be relieved with opioids. Some patients appreciate massage or other distractions, such as listening to music or to a book being read aloud.

A visit from the physician to offer care and reassurance is invaluable to the patient and family. An interdisciplinary approach, such as that provided by hospice, can be very helpful.

Final Comment

This two-part article has focused on some of the most common symptoms patients may experience at the end of life. Dying patients may also suffer from other symptoms, including pressure sores, edema, ascites, bowel impaction, diarrhea, hemoptysis, pleural effusions, incontinence, urinary retention, hematuria and fever. The management of these disorders is discussed in various palliative care textbooks and training programs.15,3539

The End-of-Life Physicians Education Resource is a superb Internet source for palliative care–related educational materials (http://www.eperc.mcw.edu). For no charge, the entire Education for Physicians on End-of-Life Care Participant's Handbook can be downloaded from the Internet (http://www.epec.net/content/participantshandbook.html).

Note that health care providers should use clinical judgment and consult official prescribing information before any pharmaceutical product mentioned in this article is used in terminally ill patients.

The authors indicate that they do not have any conflicts of interest. Sources of funding: Dr. Ross's work is supported in part by grant R25-CA66940 from the National Institutes of Health, National Cancer Institute. Dr. Alexander's work is supported in part by the Ryan White Care Act Projects of National Significance, from the Health Resources and Services Administration.

REFERENCES

1. Hallenbeck J, Weissman D. Fast fact and concepts #15: Constipation—what makes us go. June, 2000. End-of-Life Physician Education Resource Center. Retrieved April 23, 2001, from: http://www.eperc.mcw.edu.

2. Ripamonti C, De Conno F, Ventafridda V, Rossi B, Baines MJ. Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol. 1993;4:15–21.

3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994.

4. Shuster JL. Delirium, confusion and agitation at the end of life. J Palliat Med. 1998;1:177–86.

5. Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160:786–94.

6. Inouye SK. Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med. 2000;32:257–63.

7. McGuire BE, Basten CJ, Ryan CJ, Gallagher J. Intensive care unit syndrome: a dangerous misnomer. Arch Intern Med. 2000;160:906–9.

8. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153:231–7.

9. Miller FG, Meier DE. Voluntary death: a comparison of terminal dehydration and physician-assisted suicide. Ann Intern Med. 1998;128:559–62.

10. Quill TE, Lo B, Brock DW. Palliative options of last resort: a comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia. JAMA. 1997;278:2099–104.

11. Quill TE, Byock IR. Responding to intractable terminal suffering: the role of terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians–American Society of Internal Medicine. Ann Intern Med. 2000;132:408–14.

12. Lawlor PG, Fainsinger RL, Bruera ED. Delirium at the end of life: critical issues in clinical practice and research. JAMA. 2000;284:2427–9.

13. Fernandez F, Levy JK, Mansell PW. Management of delirium in terminally ill AIDS patients. Int J Psychiatry Med. 1989;19:165–72.

14. Breitbart W, Jacobsen PB. Psychiatric symptom management in terminal care. Clinics Geriatr Med. 1996;12:329–47.

15. Berger A, Portenoy RK, Weissman DE, eds. Principles and practice of supportive oncology. Philadelphia: Lippincott-Raven, 1998.

16. Module 4: Palliative care. In: Tobin MA, et al., eds. A comprehensive guide for the care of persons with HIV disease. Mississauga, Ontario: College of Family Physicians of Canada, 1993.

17. Sims R, Moss VA. Palliative care for people with AIDS. London: E. Arnold, 1995.

18. Carr DB, ed. Pain in HIV/AIDS = La douleur du SID/HIV: proceedings of a workshop convened by France-USA Pain Association (Association Douleur France-Amerique, “ADFA”) at the Council of Europe, Strasbourg, and the Medical School of the University of Strasbourg, on 7-9 October, 1994. Washington, D.C.: R.G. Addison, 1994.

19. Vogl D, Rosenfeld B, Breitbart W, Thaler H, Passik S, McDonald M, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage. 1999;18:253–62.

20. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest. 1986;89:234–6.

21. Steinmetz D, Walsh M, Gable LL, Williams PT. Family physicians' involvement with dying patients and their families. Attitudes, difficulties, and strategies. Arch Fam Med. 1993;2:753–60.

22. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 1990;142:1009–14.

23. Elliott MW, Adams L, Cockcroft A, MacRae KD, Murphy K, Guz A. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis. 1991;144:826–32.

24. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580–6.

25. Higginson I, McCarthy M. Measuring symptoms in terminal cancer: are pain and dyspnoea controlled? J R Soc Med. 1989;82:264–7.

26. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A:635–42.

27. Dudgeon D, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage. 1998;16:212–9.

28. Light RW, Muro JR, Sato RI, Stansbury DW, Fischer CE, Brown SE. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989;139:126–33.

29. Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double–blind controlled trial. Ann Oncol. 1999;10:1511–4.

30. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;1576 pt 1:1877–80.

31. Masood AR, Reed JW, Thomas SH. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995;50:629–34.

32. Leung R, Hill P, Burdon J. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996;51:596–600.

33. Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med. 1997;11:277–81.

34. Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med. 1996;153:1515–8.

35. Module 10: Common physical symptoms. In: Education for physicians on end-of-life care. Chicago: EPEC Project, Robert Wood Johnson Foundation, 1999.

36. Storey P. Primer of palliative care. 2d ed. rev. Gainesville, Fla.: American Academy of Hospice and Palliative Medicine, 1996.

37. Doyle D, Hanks GW, MacDonald N, eds. Oxford Textbook of palliative medicine. New York: Oxford University Press, 1993.

38. Joishy SK. Palliative medicine secrets. Philadelphia: Hanley & Belfus, 1999.

39. Storey P, Knight CF. UNIPAC four: Management of selected nonpain symptoms in the terminally Ill. In: Hospice/palliative care training for physicians: a self-study program. Gainesville, Fla.: American Academy of Hospice and Palliative Medicine, 1996.

This is part of a series of articles and features on issues in end-of-life care. Coordinator of this series is Caroline Wellbery, M.D., assistant deputy editor of AFP.


Copyright © 2001 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article